10 01, 2024

Baby Powder Lawsuits Hurt JNJ while Closing Several Acquisitions; Down 11% in 2023, Is it a Sell?

By |2024-01-10T19:20:12+00:00January 10th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Johnson & Johnson (JNJ) is known for baby products and the single-shot COVID-19 vaccine, making it a significant booster if you invested before the pandemic. However, following recent lawsuits, JNJ settled to pay $700 million following an investigation over its baby powder, while the COVID-19 vaccine was discontinued in the US, leading to an [...]

13 12, 2023

Pfizer Falls to 10-Year Low on Weak Forecast for 2024: 3 Reasons to Sell This Stock ASAP

By |2023-12-13T17:56:27+00:00December 13th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Pfizer (PFE) fell 9% in Wednesday morning trading after the company’s weak forecast for 2024 left much to be desired in the eyes of investors and analysts alike. The stock is headed toward a 10-year low, and has now shed 50% of its value in the last year alone. The drugmaker has been steadily [...]

17 10, 2023

Johnson & Johnson Beats Earnings & Raises Forecast – So Why is the Stock Falling?

By |2023-12-07T19:49:36+00:00October 17th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Yesterday, we highlighted Pfizer’s challenges in pivoting as a post-pandemic company. Today, its competitor Johnson & Johnson (JNJ) reported earnings itself.  But, Johnson & Johnson painted an entirely different picture - beating out the earnings estimate on the top and bottom line while raising the forecast for the remainder of the year. The company [...]

16 10, 2023

Why is Pfizer Up 5% After Cutting Sales Outlook? 3 Things Investors Need to See

By |2023-12-07T19:49:39+00:00October 16th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Pfizer (PFE) ended last week on a sour note, announcing after the market closed on Friday that it will cut $9 billion from its sales outlook. And yet, the stock is up more than 5% so far in Monday morning’s trading session. The full-year EPS has been adjusted to $1.45 to $1.65 on revenue [...]

20 07, 2023

Johnson & Johnson Jumps 6% on Earnings Beat and Revised Guidance: Does it Deserve a Buy?

By |2023-12-07T20:46:04+00:00July 20th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

Johnson & Johnson (JNJ) has had its ups and downs over the past few months, but it appears as if steady growth is ahead. The company has boosted its previous guidance for the year after Thursday’s earnings report came in well above analyst expectations. Johnson & Johnson saw sales growth of 6.3% for the [...]

26 06, 2023

Eli Lilly is Up 38% in the Past 3 Months: What Keeps Pushing the Stock Higher, and Will it Continue?

By |2023-12-07T20:46:59+00:00June 26th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]

Go to Top